Gao Jingwei, Zhang Kun, Chen Jie, Wang Mong-Heng, Wang Jingfeng, Liu Pinming, Huang Hui
Department of Cardiology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou 510120 China; Guangdong Province Key Laboratory of Arrhythmia and Electrophysiology, Guangzhou 510120, China.
Guangdong Province Key Laboratory of Arrhythmia and Electrophysiology, Guangzhou 510120, China; Department of Radiation Oncology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou 510120, China.
Eur J Pharmacol. 2016 Sep 5;786:186-193. doi: 10.1016/j.ejphar.2016.05.030. Epub 2016 May 26.
Both clinical and experimental studies have demonstrated that vascular calcification (VC) is a common pathology shared in many chronic diseases such as chronic kidney disease (CKD) and diabetes. It's an independent risk factor for cardiovascular events. Since the pathogenesis of VC is complicated, current therapies have limited effects on the regression of VC. Therefore, it is urgent to investigate the potential mechanisms and find new targets for the treatment of VC. Aldosterone (Aldo), a mineralocorticoid hormone, is the metabolite of renin-angiotensin-aldosterone system (RAAS) activation, which can exert genomic and non-genomic effects on the cardiovascular system. Recent data suggests that Aldo can promote VC. Here, we summarized the roles of Aldo in the process of VC and a series of findings indicated that Aldo could act as a potentially therapeutic target for treating VC.
临床和实验研究均表明，血管钙化（VC）是许多慢性疾病（如慢性肾脏病（CKD）和糖尿病）共有的常见病理表现。它是心血管事件的独立危险因素。由于VC的发病机制复杂，目前的治疗方法对VC消退的效果有限。因此，迫切需要研究其潜在机制并寻找治疗VC的新靶点。醛固酮（Aldo）是一种盐皮质激素，是肾素-血管紧张素-醛固酮系统（RAAS）激活的代谢产物，可对心血管系统产生基因组和非基因组效应。最近的数据表明，Aldo可促进VC。在此，我们总结了Aldo在VC过程中的作用，一系列研究结果表明，Aldo可能成为治疗VC的潜在治疗靶点。
